Amedeo Smart

Free Medical Literature Service

 

Amedeo

Anemia
  Free Subscription

Articles published in
Am J Hematol
    March 2026
  1. LIU W, Kassasseya C, Papamanolis L, Nguyen-Peyre KA, et al
    Vascular Geometry Drives Stroke Risk in Sickle Cell Disease.
    Am J Hematol. 2026;101:477-486.
    >> Share

  2. ABDELHAY A, Reghis M, Salhab T, Jadhav N, et al
    Impact of Optimizing the Lower Limit of Normal for Ferritin on Iron Deficiency Diagnosis and Treatment Patterns: A Pre and Post-Intervention Study Using EHR Data.
    Am J Hematol. 2026;101:439-446.
    >> Share

    February 2026
  3. FAY ME, Tandon R, Latham T, Lee AJ, et al
    Artificial Intelligence-Based Analysis of Central Nervous System Vasculopathy in Pediatric Sickle Cell Anemia.
    Am J Hematol. 2026 Feb 22. doi: 10.1002/ajh.70251.
    >> Share

  4. NAAMANSEN AB, Tranekaer S, Christensen F, Nielsen IE, et al
    Acquired Hemolytic Anemia Is Associated With Higher Risk of Symptomatic Gallstone Disease.
    Am J Hematol. 2026 Feb 16. doi: 10.1002/ajh.70249.
    >> Share

  5. WALTER J, Isfort P, Isfort S, Panse J, et al
    Magnetic Resonance Imaging as a Complementary Diagnostic Tool for Aplastic Anemia.
    Am J Hematol. 2026 Feb 14. doi: 10.1002/ajh.70236.
    >> Share

  6. BARCELOS GT, Peixoto T, Alvir J, Lin J, et al
    Economic Burden of Sickle Cell Disease: A Retrospective Study of Pediatric and Adult Individuals With Medicaid Coverage From 2016 to 2020.
    Am J Hematol. 2026;101:269-280.
    >> Share

  7. ROTH A, Barcellini W, Ademokun C, Jang J, et al
    Iptacopan for Immune Thrombocytopenia and Cold Agglutinin Disease: A Global Phase 2 Basket Clinical Trial.
    Am J Hematol. 2026;101:242-254.
    >> Share

    January 2026
  8. LANIKOVA L, Hrckulak D, Zimolova V, Lorenzo FR, et al
    Autosomal Dominant Erythrocytosis Caused by Non-Renal Erythropoietin (EPO) Due to EPO c.-136 G>A Germline Mutation.
    Am J Hematol. 2026 Jan 23. doi: 10.1002/ajh.70208.
    >> Share

  9. WEYAND AC, Triebwasser JE, Chaitoff A
    Prevalence of Iron Deficiency and Iron Deficiency Anemia in US Pregnant Individuals, 2003-2023.
    Am J Hematol. 2026 Jan 15. doi: 10.1002/ajh.70207.
    >> Share

  10. TEFFERI A, Abdelmagid M, Palmer JM, Al-Kali A, et al
    Post-FDA Approval Experience With Momelotinib in JAK Inhibitor-Naive Myelofibrosis: Focus on Anemia Response and Treatment-Emergent Nephropathy and Peripheral Neuropathy.
    Am J Hematol. 2026 Jan 8. doi: 10.1002/ajh.70203.
    >> Share

  11. FORNI GL, Stampone E, Pinto VM, Silvestri L, et al
    Iron Overload and Anemia in Transferrin Immune Complex Disease, an Overlooked Monoclonal Gammopathy of Clinical Significance.
    Am J Hematol. 2026 Jan 7. doi: 10.1002/ajh.70187.
    >> Share

  12. LECORNEC N, de Fontbrune FS, Forcade E, Garcon L, et al
    Hematologic Landscape of Adult Patients With Diamond-Blackfan Anemia Syndrome.
    Am J Hematol. 2026 Jan 7. doi: 10.1002/ajh.70197.
    >> Share

  13. BENOTTI PN, Wood GC, Kaberi-Otarod J, Still CD, et al
    Preoperative Iron Status and the Risk of Severe Postoperative Anemia After Metabolic and Bariatric Surgery.
    Am J Hematol. 2026 Jan 6. doi: 10.1002/ajh.70191.
    >> Share

  14. ZHANG L, Li R, Liang Q, Li W, et al
    Hetrombopag Added to Cyclosporine as the First-Line Treatment for Patients With Non-Severe Aplastic Anemia: A Phase 2 Multicenter Trial.
    Am J Hematol. 2026 Jan 5. doi: 10.1002/ajh.70183.
    >> Share

  15. IDRISS S, Hoogewijs D, Girodon F, Gardie B, et al
    Erythropoietin Expression and Regulation: Piecing Together Known Mechanisms and Emerging Insights.
    Am J Hematol. 2026 Jan 3. doi: 10.1002/ajh.70173.
    >> Share

  16. HUANG L, Wang Q, Li HL, Peng W, et al
    Flu/Cy Plus PTCy Conditioning Regimen in Haplo-HSCT of Severe Aplastic Anemia.
    Am J Hematol. 2026 Jan 3. doi: 10.1002/ajh.70176.
    >> Share

  17. BENSON AE, Martens KL, Rincon M, Ward L, et al
    Efficacy of Single-Dose Intravenous Ferric Derisomaltose for Iron Deficiency Anemia in Pregnancy.
    Am J Hematol. 2026 Jan 2. doi: 10.1002/ajh.70190.
    >> Share

  18. REES CA, Hatabah D, Korman R, Ahmad F, et al
    Hospital Variations in Time-To-Crisis-Resolution Among Children and Adolescents With Sickle Cell Disease.
    Am J Hematol. 2026;101:206-212.
    >> Share

  19. AUDITEAU C, Fricot A, Gauthier R, Sissoko A, et al
    Protein S Enhances the Phagocytosis of Phosphatidylserine-Exposing Erythrocytes: Implications in Sickle Cell Disease.
    Am J Hematol. 2026;101:26-40.
    >> Share

  20. MUSALLAM KM, Vitrano A, Inzerillo A, Di Maggio R, et al
    Quantifying Morbidity Risk Attributed to Red-Cell Transfusion Volume in Optimally Transfused Patients With beta-Thalassemia.
    Am J Hematol. 2026;101:149-151.
    >> Share

    December 2025
  21. COHEN RT, Hankins JS, Ness KK, Hsu LL, et al
    Acute Exercise Challenge and Airway Dynamics in Youth With Sickle Cell Anemia: A Multicenter Study.
    Am J Hematol. 2025 Dec 20. doi: 10.1002/ajh.70170.
    >> Share

  22. RIEZ C, Leroux A, Lopes ME, Kamdem A, et al
    Reversal of Echocardiographic Alterations Following Hematopoietic Stem Cell Transplantation in Children With Sickle-Cell Anemia.
    Am J Hematol. 2025 Dec 7. doi: 10.1002/ajh.70163.
    >> Share

  23. BARTOLUCCI P, Audureau E, Audard V, Galacteros F, et al
    Albuminuria Predicts a Rapid Decline in Kidney Function in 2 International, Longitudinal Cohorts of Adults With Sickle Cell Anemia.
    Am J Hematol. 2025 Dec 3. doi: 10.1002/ajh.70155.
    >> Share

  24. LIANG P, Wan YS, Shan KZ, Chou R, et al
    Targeting PIEZO1-TMEM16F Coupling to Mitigate Sickle Cell Disease Complications.
    Am J Hematol. 2025;100:2261-2275.
    >> Share

  25. HEMMER M, Moinard S, Lambotte O, Malphettes M, et al
    Pure Red Cell Aplasia Associated With Thymic Tumors, a Nationwide Retrospective Study.
    Am J Hematol. 2025;100:2230-2237.
    >> Share

    November 2025
  26. ESFAHANI PR, Nguyen TB, Reddy A, Yong A, et al
    Advancing Anemia Detection With Deep Neural Networks: A Comparative Analysis of Training Strategies Using Conjunctival Images.
    Am J Hematol. 2025 Nov 22. doi: 10.1002/ajh.70143.
    >> Share

  27. QUARELLO P, Karimi K, Trajkova S, Garelli E, et al
    DNA Methylation Episignature as a Novel Diagnostic Tool for Diamond-Blackfan Anemia Syndrome.
    Am J Hematol. 2025 Nov 17. doi: 10.1002/ajh.70141.
    >> Share

  28. KAPHAN E, Walter-Petrich A, Larcher L, Leblanc T, et al
    Recursive Partitioning to Differentiate Acquired From Inherited Bone Marrow Failure Syndromes.
    Am J Hematol. 2025;100:1983-1992.
    >> Share

  29. FATTIZZO B, Pedone GL, Metafuni E, Beggiato E, et al
    Characterization of Breakthrough Hemolysis in Patients With Paroxysmal Nocturnal Hemoglobinuria: An International Multicenter Experience.
    Am J Hematol. 2025;100:1963-1971.
    >> Share

  30. SIMON T, Savale L, Grundtvig Skaarup K, Breillat P, et al
    Sickle Cell Diastolic Cardiomyopathy and Mortality Risk: A Novel Echocardiographic Framework for Prognostic Stratification.
    Am J Hematol. 2025;100:1940-1951.
    >> Share

    October 2025
  31. MABERRY MD, Smith CJ, Go RS
    Clinical Utility of Monoclonal Gammopathy Testing in the Evaluation of Anemia.
    Am J Hematol. 2025 Oct 23. doi: 10.1002/ajh.70102.
    >> Share

  32. GANGAT N, Tefferi A
    The Hemojuvelin-Hepcidin Axis as a Target for the Treatment of Anemia or Conversely Polycythemia.
    Am J Hematol. 2025 Oct 21. doi: 10.1002/ajh.70120.
    >> Share

  33. AL-SAMKARI H, Mayne TJ, Troutt M, Patle H, et al
    Characterizing the Healthcare Utilization and Costs of Hereditary Hemorrhagic Telangiectasia.
    Am J Hematol. 2025;100:1722-1735.
    >> Share

    September 2025
  34. COATES TD
    Early Detection of Diastolic Dysfunction in Sickle Cell Anemia: Can It Help the Patient and Let Us See the Elephant in the Room?
    Am J Hematol. 2025 Sep 24. doi: 10.1002/ajh.70073.
    >> Share

  35. ZAIMOKU Y, Yamazaki H, Kanaya M, Hiramoto N, et al
    Loss-Prone HLA Class I Alleles Inform Outcomes of Early Hematopoietic Cell Transplantation in Acquired Aplastic Anemia.
    Am J Hematol. 2025 Sep 5. doi: 10.1002/ajh.70054.
    >> Share

  36. CHEVALIER K, Holub M, Palich R, Blanckaert K, et al
    Cold Agglutinin Syndrome Secondary to Mycoplasma pneumoniae Infection in Adults: Results From a Large French Observational Study (MyCOLD Study).
    Am J Hematol. 2025;100:1557-1565.
    >> Share

  37. ZADRO Y, Lusque A, Rey H, Cougoul P, et al
    Durable Responses With Front-Line Rituximab in Autoimmune Cytopenias Associated With Indolent B-Cell Clones.
    Am J Hematol. 2025;100:1670-1674.
    >> Share

    August 2025
  38. ANDERSON JR, Hollenhorst MA
    Double Bite Cells in Oxidative Hemolytic Anemia.
    Am J Hematol. 2025 Aug 13. doi: 10.1002/ajh.70035.
    >> Share

    July 2025
  39. AMARU R, Prchal J, Carrasco M, Mancilla S, et al
    History of Thrombosis at High Altitude Associates With Increased Erythropoietin.
    Am J Hematol. 2025 Jul 30. doi: 10.1002/ajh.70025.
    >> Share

  40. HUET S, Kamdem A, Beaufront V, Yakouben K, et al
    Reversal of Glomerular Hyperfiltration Following Hematopoietic Stem Cell Transplantation in Children With Sickle-Cell Anemia.
    Am J Hematol. 2025 Jul 16. doi: 10.1002/ajh.70004.
    >> Share

  41. BOULARES A, Bragazzi NL, Gonzales GF, Robach P, et al
    Addressing Anemia in High-Altitude Populations: Global Impact, Prevalence, Challenges, and Potential Solutions.
    Am J Hematol. 2025 Jul 2. doi: 10.1002/ajh.27761.
    >> Share

  42. MORRIS CR, Hatabah D, Korman R, Gillespie S, et al
    Arginine Therapy for Pain in Sickle Cell Disease: A Phase-2 Randomized, Placebo-Controlled Trial.
    Am J Hematol. 2025;100:1119-1131.
    >> Share

  43. WANG D, Sra M, Glaeser-Khan S, Wang DY, et al
    Cost-Effectiveness of Ferritin Screening Thresholds for Iron Deficiency in Reproductive-Age Women.
    Am J Hematol. 2025;100:1132-1140.
    >> Share

    June 2025
  44. BREWIN J, Clark B, Smith F, Parkin N, et al
    Loss of Function SPTA1 Variants Causes Neonatal Liver Failure and Fetal Anemia.
    Am J Hematol. 2025 Jun 26. doi: 10.1002/ajh.27751.
    >> Share

  45. MAFFIOLI M, Mora B, Iurlo A, Elli EM, et al
    The 2024 Three-Strata Baseline Anemia Definition of the Revised IWG-ELN Criteria Dissects Survival in Ruxolitinib-Treated Myelofibrosis Patients.
    Am J Hematol. 2025 Jun 6. doi: 10.1002/ajh.27734.
    >> Share

  46. RICCI E, Bagnasco F, Pierri F, Risitano A, et al
    Long-Term Outcome of Fanconi Anemia Patients From the Italian Registry on Behalf of the Marrow Failure Study Group of the AIEOP (Italian Association for Pediatric Haematology-Oncology).
    Am J Hematol. 2025 Jun 6. doi: 10.1002/ajh.27724.
    >> Share

    May 2025
  47. JACOBS JW, Raza S, Clark LM, Stephens LD, et al
    Mixed Autoimmune Hemolytic Anemia: A Systematic Review of Epidemiology, Clinical Characteristics, Therapies, and Outcomes.
    Am J Hematol. 2025 May 20. doi: 10.1002/ajh.27721.
    >> Share

  48. MEJIAS-FIGUEROA JA, Rodeghier M, DeBaun MR
    Impact of Switching From Race-Based to Race-Neutral Spirometry Reference Equations in Children With Sickle Cell Anemia.
    Am J Hematol. 2025 May 12. doi: 10.1002/ajh.27704.
    >> Share

  49. BESHAI M, Alhomsi N, Warkentin TE
    Thrombocytopenia and Anemia After Cardiac Surgery.
    Am J Hematol. 2025 May 2. doi: 10.1002/ajh.27696.
    >> Share

  50. TRAETS MJM, Bos JF, van der Veen S, van Pelt L, et al
    Pyruvate Kinase Function Correlates With Red Blood Cell Properties and Clinical Manifestations in Sickle Cell Disease.
    Am J Hematol. 2025;100:785-796.
    >> Share

  51. MAGAGNOLI J, Knopf K, Hrushesky WJ, Carson KR, et al
    Ferric Carboxymaltose (FCM)-Associated Hypophosphatemia (HPP): A Systematic Review.
    Am J Hematol. 2025;100:840-846.
    >> Share

    April 2025
  52. ZAHR RS, Kang G, Zhang X, Rashkin SR, et al
    Development of Polygenic Risk Score for Persistent Albuminuria in Children and Adults With Sickle Cell Anemia.
    Am J Hematol. 2025 Apr 5. doi: 10.1002/ajh.27678.
    >> Share

    March 2025
  53. GANGAT N, Tefferi A
    Emerging Pathogenetic Mechanisms and New Drugs for Anemia in Myelofibrosis and Myelodysplastic Syndromes.
    Am J Hematol. 2025 Mar 8. doi: 10.1002/ajh.27659.
    >> Share

  54. JIANG D, Sampino EV, Rosenlind K, Campagna DR, et al
    Expanding the Phenotype of DNA Ligase 1 Deficiency: First Report of Macrocytic Sideroblastic Anemia.
    Am J Hematol. 2025 Mar 7. doi: 10.1002/ajh.27649.
    >> Share

    February 2025
  55. NAAMANSEN AB, Hansen DL, Petersen J, Glenthoj A, et al
    10-Year Risk of Gallstones in Congenital Red Blood Cell Disorder Patients: A Nationwide Cohort Study.
    Am J Hematol. 2025;100:229-235.
    >> Share

    January 2025
  56. FATTIZZO B, Gurnari C, Giammarco S, Ricchiuti A, et al
    Elderly Patients With Aplastic Anemia: Treatment Patterns and Outcomes in the Real World.
    Am J Hematol. 2025 Jan 29. doi: 10.1002/ajh.27611.
    >> Share

  57. WANG CY, Melgar-Bermudez E, Welch D, Dagbay KB, et al
    A Recombinant Antibody Against ALK2 Promotes Tissue Iron Redistribution and Contributes to Anemia Resolution in a Mouse Model of Anemia of Inflammation.
    Am J Hematol. 2025 Jan 10. doi: 10.1002/ajh.27578.
    >> Share

  58. KONTE K, Afzali-Hashemi L, Baas KPA, Schrantee A, et al
    Effect of voxelotor on cerebral perfusion and cerebral oxygen metabolism and cardiac stress in adult patients with sickle cell disease.
    Am J Hematol. 2025;100:78-84.
    >> Share

  59. ROSATO BE, D'Onofrio V, Marra R, Nostroso A, et al
    RAS signaling pathway is essential in regulating PIEZO1-mediated hepatic iron overload in dehydrated hereditary stomatocytosis.
    Am J Hematol. 2025;100:52-65.
    >> Share

  60. BOU-FAKHREDIN R, Cappellini MD, Taher AT, De Franceschi L, et al
    Hypercoagulability in hemoglobinopathies: Decoding the thrombotic threat.
    Am J Hematol. 2025;100:103-115.
    >> Share

    December 2024
  61. LIN X, Yang C, Zhuang J, Li J, et al
    Rituximab Plus Bortezomib for Relapsed and Refractory Warm Autoimmune Hemolytic Anemia: A Prospective Phase 2 Trial.
    Am J Hematol. 2024 Dec 21. doi: 10.1002/ajh.27540.
    >> Share

  62. STUTE P, Akpan IJ, Breymann C, Murji A, et al
    Effect of Ferric Derisomaltose on Fatigue in Iron Deficiency Anemia Associated With Abnormal Uterine Bleeding.
    Am J Hematol. 2024 Dec 12. doi: 10.1002/ajh.27555.
    >> Share

  63. SISSOKO A, Cisse A, Duverdier C, Marin M, et al
    Clearance of pathogenic erythrocytes is maintained despite spleen dysfunction in children with sickle cell disease.
    Am J Hematol. 2024;99:2267-2278.
    >> Share

    November 2024
  64. RAMIREZ MJ, Pujol R, Minguillon J, Bogliolo M, et al
    Prognostic significance of mutation type and chromosome fragility in Fanconi anemia.
    Am J Hematol. 2024 Nov 19. doi: 10.1002/ajh.27520.
    >> Share

  65. MOSTAFA MA, Zand M, Taylor J, Kouides P, et al
    Successful 13-year ongoing remission with C5 inhibitor therapy following renal transplant in atypical hemolytic uremic syndrome.
    Am J Hematol. 2024;99:2241-2243.
    >> Share

  66. KULASEKARARAJ A, Lanza F, Arvanitakis A, Langemeijer S, et al
    Comparative clinical efficacy and safety of biosimilar ABP 959 and eculizumab reference product in patients with paroxysmal nocturnal hemoglobinuria.
    Am J Hematol. 2024;99:2108-2117.
    >> Share

  67. VAN DOREN L, Brugnara C
    Self-pay laboratory charges for iron deficiency diagnosis in the Boston and New Haven metropolitan areas.
    Am J Hematol. 2024;99:2233-2235.
    >> Share

  68. CUMMINGS OW, Rahman S, Fletcher L, Scott AW, et al
    Advances in sickle cell retinopathy screening techniques, tests, and practices: A systematic review.
    Am J Hematol. 2024;99:2152-2163.
    >> Share

  69. LAL A, Viprakasit V, Vichinsky E, Lai Y, et al
    Disease burden, management strategies, and unmet needs in alpha-thalassemia due to hemoglobin H disease.
    Am J Hematol. 2024;99:2164-2177.
    >> Share

    October 2024
  70. BARCELLINI W, Pane F, Patriarca A, Murakhovskaya I, et al
    Parsaclisib for the treatment of primary autoimmune hemolytic anemia: Results from a phase 2, open-label study.
    Am J Hematol. 2024 Oct 22. doi: 10.1002/ajh.27493.
    >> Share

  71. CONNES P, Stauffer E, Liem RI, Nader E, et al
    Exercise and training in sickle cell disease: Safety, potential benefits, and recommendations.
    Am J Hematol. 2024;99:1988-2001.
    >> Share

  72. ARNOLD SD, Bakshi N, Ross D, Smith C, et al
    Long-term quality of life after hematopoietic cell transplant for sickle cell disease in childhood: A STELLAR interim analysis.
    Am J Hematol. 2024;99:2037-2040.
    >> Share

  73. CASELLA JF, Furstenau DK, Adams RJ, Brambilla DJ, et al
    Hydroxyurea to prevent brain injury in children with sickle cell disease (HU Prevent)-A randomized, placebo-controlled phase II feasibility/pilot study.
    Am J Hematol. 2024;99:1906-1916.
    >> Share

    September 2024
  74. BOUCHER AA, Dayton VJ, Pratt AR, Nassar NN, et al
    Three-generation female cohort with macrocytic anemia and iron overload.
    Am J Hematol. 2024 Sep 27. doi: 10.1002/ajh.27489.
    >> Share

  75. DELAFOY M, Dalle JH, Pondarre C, Andrieu GP, et al
    Assessing acute toxicity profiles of HLA-identical hematopoietic stem cell transplantation in pediatric patients with sickle cell anemia: A comprehensive analysis on behalf of the SFGM-TC.
    Am J Hematol. 2024 Sep 24. doi: 10.1002/ajh.27486.
    >> Share

  76. YOUNG DJ
    A growing panoply of options for patients with paroxysmal nocturnal hemoglobinuria.
    Am J Hematol. 2024;99:1667-1669.
    >> Share

  77. SCHEINBERG P, Cle DV, Kim JS, Nur E, et al
    Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria.
    Am J Hematol. 2024;99:1757-1767.
    >> Share

  78. TORRES C, Galadanci N, Osborn J, Kanter J, et al
    Real-world implementation of the David-Carroll buprenorphine protocol for pain management in sickle cell disease.
    Am J Hematol. 2024;99:1834-1836.
    >> Share

  79. ROTH A, He G, Tong H, Lin Z, et al
    Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition.
    Am J Hematol. 2024;99:1768-1777.
    >> Share

    August 2024
  80. MEANS RT JR, Bi C, Wong ECC, Bare LA, et al
    Ferritin reference intervals in a population of working-age adults without anemia.
    Am J Hematol. 2024 Aug 5. doi: 10.1002/ajh.27444.
    >> Share

  81. ACHOUR A, Knijnenburg J, Koopmann T, Raz A, et al
    Moderate-severe beta-thalassemia intermedia phenotype caused by sextuplicated alpha-globin gene allele in two beta-thalassemia carriers.
    Am J Hematol. 2024;99:1655-1658.
    >> Share

  82. YU EA, Zacharias HU, Kelly S, Vichinsky E, et al
    Improving healthspan among people with sickle cell disease: Leveraging precision health in an era of treatments with curative intent.
    Am J Hematol. 2024;99:1456-1458.
    >> Share

  83. BORTOLOTTI M, Trikha R, Salter S, Large J, et al
    Pregnancy in acquired bone marrow failure syndromes: Antenatal management and maternal and fetal outcomes.
    Am J Hematol. 2024;99:1647-1650.
    >> Share

  84. ITO S, Wang D, Purcell A, Chetlapalli K, et al
    Cost-effectiveness of sutimlimab in cold agglutinin disease.
    Am J Hematol. 2024;99:1475-1484.
    >> Share

  85. DOVERN E, Aydin M, Hazenberg MD, Tang MW, et al
    Azathioprine/hydroxyurea preconditioning prior to nonmyeloablative matched sibling donor hematopoietic stem cell transplantation in adults with sickle cell disease: A prospective observational cohort study.
    Am J Hematol. 2024;99:1523-1531.
    >> Share

  86. WEN S, Nisenbaum R, Weyand AC, Tang GH, et al
    High prevalence of iron deficiency and socioeconomic disparities in laboratory screening of non-pregnant females of reproductive age: A retrospective cohort study.
    Am J Hematol. 2024;99:1492-1499.
    >> Share

  87. BORGEY M, Genty I, Habibi A, Arlet JB, et al
    High risk of progression for chronic major organ complications of sickle cell disease in adolescents and young adults: A long-term neonatal cohort study.
    Am J Hematol. 2024;99:1601-1605.
    >> Share

  88. VUONG C, Eckhardt CL, Heijboer H, Suijker MH, et al
    Long-term follow-up of children with sickle cell disease diagnosed by newborn screening in the Netherlands: Overview of morbidity and mortality.
    Am J Hematol. 2024;99:1606-1609.
    >> Share

  89. SUN R, Srivastava A, Derebail VK, Han J, et al
    GLP-1 agonists and SGLT-2 inhibitors in adults with sickle cell disease.
    Am J Hematol. 2024;99:1610-1612.
    >> Share

  90. LUGTHART G, Verweij EJT, Harteveld CL, Tan RNGB, et al
    Suppression of Hb Bart's to improve tissue oxygenation and fetal development in homozygous alpha-thalassemia.
    Am J Hematol. 2024;99:1613-1615.
    >> Share

    July 2024
  91. VINCHI F
    New partners for Luspatercept in beta-thalassemia.
    Am J Hematol. 2024;99:1217-1219.
    >> Share

  92. KUO KHM, Grace RF, van Beers EJ, Barcellini W, et al
    Clinically meaningful improvements in patient-reported outcomes in mitapivat-treated patients with pyruvate kinase deficiency.
    Am J Hematol. 2024;99:1415-1419.
    >> Share

  93. GUERRA A, Hamilton N, Rivera A, Demsko P, et al
    Combination of a TGF-beta ligand trap (RAP-GRL) and TMPRSS6-ASO is superior for correcting beta-thalassemia.
    Am J Hematol. 2024;99:1300-1312.
    >> Share

  94. PLACAIS M, Laparra A, Maria ATJ, Kramkimel N, et al
    Drug-induced autoimmune hemolytic anemias related to immune checkpoint inhibitors, therapeutic management, and outcome.
    Am J Hematol. 2024;99:1427-1430.
    >> Share

  95. TANZI E, Di Modica SM, Bordini J, Olivari V, et al
    Bone marrow Tfr2 deletion improves the therapeutic efficacy of the activin-receptor ligand trap RAP-536 in beta-thalassemic mice.
    Am J Hematol. 2024;99:1313-1325.
    >> Share

  96. WANG Z, Jiang B, Song L, Sun M, et al
    Patients with acquired pure red cell aplasia respond to PI3Kdelta inhibitor rapidly.
    Am J Hematol. 2024;99:1431-1433.
    >> Share

  97. CASTRO OL, De Franceschi L, Ganz T, Kanter J, et al
    Iron restriction in sickle cell disease: When less is more.
    Am J Hematol. 2024;99:1349-1359.
    >> Share

  98. VAN DOREN L, Steinheiser M, Boykin K, Taylor KJ, et al
    Expert consensus guidelines: Intravenous iron uses, formulations, administration, and management of reactions.
    Am J Hematol. 2024;99:1338-1348.
    >> Share

    June 2024
  99. GANGAT N, Tefferi A
    Targeting anemia in myeloid neoplasms.
    Am J Hematol. 2024 Jun 5. doi: 10.1002/ajh.27408.
    >> Share

  100. TUBMAN VN, Maysonet D, Estrada N, Halder T, et al
    Unswitched memory B cell deficiency in children with sickle cell disease and response to pneumococcal polysaccharide vaccine.
    Am J Hematol. 2024;99:1084-1094.
    >> Share

  101. RONDELLI D
    Non-myeloablative allogeneic HSCT in adult patients with sickle cell disease: Multiple take-home points from the Saudi Arabia experience.
    Am J Hematol. 2024;99:1021-1022.
    >> Share

  102. MINNITI CP
    Let's get "real" in sickle cell disease: Real-world data and long-term patients' registries.
    Am J Hematol. 2024;99:1019-1020.
    >> Share

  103. DOVERN E, Aydin M, DeBaun MR, Alizade K, et al
    Effect of allogeneic hematopoietic stem cell transplantation on sickle cell disease-related organ complications: A systematic review and meta-analysis.
    Am J Hematol. 2024;99:1129-1141.
    >> Share

  104. DAMLAJ M, Alahmari B, Alaskar A, Alhejazi A, et al
    Favorable outcome of non-myeloablative allogeneic transplantation in adult patients with severe sickle cell disease: A single center experience of 200 patients.
    Am J Hematol. 2024;99:1023-1030.
    >> Share

  105. KWIATKOWSKI JL, Thompson AA, Tricta F, Temin NT, et al
    Real-world evidence: Long-term safety of deferiprone in a large cohort of patients with sickle cell disease enrolled in a registry for up to 10 years.
    Am J Hematol. 2024;99:1031-1039.
    >> Share

  106. JACOBS JW, Stephens LD, Chooljian DM, Sharma D, et al
    Crizanlizumab and sickle cell disease: When should medications have their approval status revoked?
    Am J Hematol. 2024;99:1016-1018.
    >> Share

  107. DE LIGT LA, Gaartman AE, Biemond BJ, Fijnvandraat K, et al
    Neutrophils in sickle cell disease: Exploring their potential role as a therapeutic target.
    Am J Hematol. 2024;99:1119-1128.
    >> Share

    May 2024
  108. BROUSSE V, El Hoss S, Isnard P, Laurance S, et al
    Comparative histological analysis of spleens in pediatric patients with hemolytic anemias: Insights into the pathophysiological mechanisms of spleen destruction in sickle cell anemia.
    Am J Hematol. 2024 May 22. doi: 10.1002/ajh.27374.
    >> Share

  109. MICHEL M, Sair M, Riviere E, Moulis G, et al
    Intravenous immunoglobulin as a rescue therapy for severe adult autoimmune hemolytic anemia: Results from a French multicenter observational study.
    Am J Hematol. 2024 May 14. doi: 10.1002/ajh.27361.
    >> Share

  110. NJOKU F, Pugh N, Brambilla D, Kroner B, et al
    Mortality in adults with sickle cell disease: Results from the sickle cell disease implementation consortium (SCDIC) registry.
    Am J Hematol. 2024;99:900-909.
    >> Share

  111. GRIFFIN M, Kelly R, Brindel I, Maafa L, et al
    Real-world experience of pegcetacoplan in paroxysmal nocturnal hemoglobinuria.
    Am J Hematol. 2024;99:816-823.
    >> Share

    April 2024
  112. MARRA R, Nostroso A, Rosato BE, Esposito FM, et al
    Unveiling the genetic landscape of suspected congenital dyserythropoietic anemia type I: A retrospective cohort study of 36 patients.
    Am J Hematol. 2024 Apr 26. doi: 10.1002/ajh.27350.
    >> Share

  113. YOSHIMI A, Noellke P, Stary J, Kallay K, et al
    Comparison of outcomes of immunosuppressive therapy with rabbit versus horse antithymocyte globulin and cyclosporine a in children with acquired severe aplastic anemia.
    Am J Hematol. 2024 Apr 15. doi: 10.1002/ajh.27334.
    >> Share

  114. JACKSON TA, Buscetta AJ, Ramirez HC, Bonham VL Jr, et al
    Leg ulcers are indicators of systemic dysfunction in individuals with sickle cell disease.
    Am J Hematol. 2024;99:767-769.
    >> Share

  115. FATTIZZO B, Roth A, Broome CM, Khan U, et al
    COVID-19 vaccine safety and immunogenicity in patients with cold agglutinin disease receiving concomitant sutimlimab.
    Am J Hematol. 2024;99:789-791.
    >> Share

  116. EAPEN M, Kou J, Andreansky M, Bhatia M, et al
    Long-term outcomes after unrelated donor transplantation for severe sickle cell disease on the BMT CTN 0601 trial.
    Am J Hematol. 2024;99:785-788.
    >> Share

  117. ITO S, Pandya A, Hauser RG, Krishnamurti L, et al
    Decreasing alloimmunization-specific mortality in sickle cell disease in the United States: Cost-effectiveness of a shared transfusion resource.
    Am J Hematol. 2024;99:570-576.
    >> Share

  118. ALLALI S, Galacteros F, Oevermann L, Cannas G, et al
    Hydroxyurea is associated with later onset of acute splenic sequestration crisis in sickle cell disease: Lessons from the European Sickle Cell Disease Cohort-Hydroxyurea (ESCORT-HU) study.
    Am J Hematol. 2024;99:555-561.
    >> Share

    March 2024
  119. GIARDINO S, Eikema DJ, Piepenbroek B, Algeri M, et al
    HLA-haploidentical stem cell transplantation in children with inherited bone marrow failure syndromes: A retrospective analysis on behalf of EBMT severe aplastic Anemia and pediatric diseases working parties.
    Am J Hematol. 2024 Mar 18. doi: 10.1002/ajh.27293.
    >> Share

  120. SHORT V, Allen R, Earley CJ, Bahrain H, et al
    A randomized double-blind pilot study to evaluate the efficacy, safety, and tolerability of intravenous iron versus oral iron for the treatment of restless legs syndrome in patients with iron deficiency anemia.
    Am J Hematol. 2024 Mar 13. doi: 10.1002/ajh.27290.
    >> Share

  121. SICA M, Notaro R
    The inhibition of several components of terminal complement pathway results in C3 binding to PNH red blood cells.
    Am J Hematol. 2024;99:505-507.
    >> Share

  122. MUSALLAM KM, Barella S, Origa R, Ferrero GB, et al
    'Phenoconversion' in adult patients with beta-thalassemia.
    Am J Hematol. 2024;99:490-493.
    >> Share

  123. JACOBS JW, Booth GS, Woo JS, Adkins BD, et al
    How the United States syphilis epidemic may portend a resurgence of an unusual hematologic condition: The connection between syphilis and paroxysmal cold hemoglobinuria.
    Am J Hematol. 2024;99:484-485.
    >> Share

  124. CORBACIOGLU S, Frangoul H, Locatelli F, Hobbs W, et al
    Defining curative endpoints for transfusion-dependent beta-thalassemia in the era of gene therapy and gene editing.
    Am J Hematol. 2024;99:422-429.
    >> Share

  125. LOCATELLI F, Corbacioglu S, Hobbs W, Frangoul H, et al
    Defining curative endpoints for sickle cell disease in the era of gene therapy and gene editing.
    Am J Hematol. 2024;99:430-438.
    >> Share

    February 2024
  126. POWER-HAYS A, Tomlinson GA, Tshilolo L, Santos B, et al
    Reducing transfusion utilization for children with sickle cell anemia in sub-Saharan Africa with hydroxyurea: Analysis from the phase I/II REACH trial.
    Am J Hematol. 2024 Feb 8. doi: 10.1002/ajh.27244.
    >> Share

  127. ABDULLAHI SU, Sunusi S, Aminu H, Umar R, et al
    Transcranial doppler velocity in iron-deficient Nigerian children with sickle cell anemia.
    Am J Hematol. 2024 Feb 7. doi: 10.1002/ajh.27230.
    >> Share

  128. TEFFERI A, Pardanani A, Gangat N
    Momelotinib expands the therapeutic armamentarium for myelofibrosis: Impact on hierarchy of treatment choices.
    Am J Hematol. 2024;99:300-308.
    >> Share

  129. SOUISSI M, Daliphard S, Picard V, Lebigot E, et al
    Elevated MCHC reveals a Southeast Asian Ovalocytosis.
    Am J Hematol. 2024;99:331-332.
    >> Share

  130. CHEN M, Hankins JS, Zhang M, Ataga KI, et al
    Comparative pharmacovigilance assessment of adverse events associated with the use of hydroxyurea, L-glutamine, voxelotor, and crizanlizumab in sickle cell disease.
    Am J Hematol. 2024;99:E37-E41.
    >> Share

  131. AFZALI-HASHEMI L, Dovern E, Baas KPA, Schrantee A, et al
    Cerebral hemodynamics and oxygenation in adult patients with sickle cell disease after stem cell transplantation.
    Am J Hematol. 2024;99:163-171.
    >> Share

  132. GARBOWSKI MW, Ugidos M, Risueno A, Shetty JK, et al
    Luspatercept stimulates erythropoiesis, increases iron utilization, and redistributes body iron in transfusion-dependent thalassemia.
    Am J Hematol. 2024;99:182-192.
    >> Share

    January 2024
  133. SHAGIDOV D, Guttmann-Raviv N, Cunat S, Frech L, et al
    A newly identified ferritin L-subunit variant results in increased proteasomal subunit degradation, impaired complex assembly, and severe hypoferritinemia.
    Am J Hematol. 2024;99:12-20.
    >> Share

  134. SEIDL E, Wilson D, Odame I, Kirby-Allen M, et al
    Lung function decline in children with sickle cell disease treated with hydroxyurea.
    Am J Hematol. 2024;99:E19-E21.
    >> Share

    December 2023
  135. PINTO VM, Romano N, Balocco M, Carrara P, et al
    Reduction of extramedullary erythropoiesis and amelioration of anemia in a beta-thalassemia patient treated with thalidomide.
    Am J Hematol. 2023 Dec 26. doi: 10.1002/ajh.27189.
    >> Share

  136. SOULIE A, Kamdem A, Neumann F, Hau I, et al
    Clinical events in a long-term prospective neonatal cohort of children with sickle cell disease: Evidence for a high disease burden without systematic preventive intensification with hydroxyurea.
    Am J Hematol. 2023;98:E395-E398.
    >> Share

  137. HATEM A, Esperti S, Murciano N, Qiao M, et al
    Adverse effects of delta-9-tetrahydrocannabinol on sickle red blood cells.
    Am J Hematol. 2023;98:E383-E386.
    >> Share

  138. BARAKAT A, Jasuja R, Tomlinson L, Wenzel Z, et al
    Effects of 2,3-DPG knockout on SCD phenotype in Townes SCD model mice.
    Am J Hematol. 2023;98:1838-1846.
    >> Share

    November 2023
  139. KHO S, Siregar NC, Qotrunnada L, Fricot A, et al
    Retention of uninfected red blood cells causing congestive splenomegaly is the major mechanism of anemia in malaria.
    Am J Hematol. 2023 Nov 27. doi: 10.1002/ajh.27152.
    >> Share

  140. HONG HG, Gouveia MH, Ogwang MD, Kerchan P, et al
    Sickle cell allele HBB-rs334(T) is associated with decreased risk of childhood Burkitt lymphoma in East Africa.
    Am J Hematol. 2023 Nov 27. doi: 10.1002/ajh.27149.
    >> Share

  141. KUTER DJ, Piatek C, Roth A, Siddiqui A, et al
    Fostamatinib for warm antibody autoimmune hemolytic anemia: Phase 3, randomized, double-blind, placebo-controlled, global study (FORWARD).
    Am J Hematol. 2023 Nov 6. doi: 10.1002/ajh.27144.
    >> Share

  142. PINCEZ T, Lettre G
    Re-assessing the effect of fetal hemoglobin on stroke in the Cooperative Study of Sickle Cell Disease.
    Am J Hematol. 2023;98:E309-E311.
    >> Share

  143. THOMAS B, Visanica S, Poussing S, Gerard D, et al
    Is this really thalassemia?
    Am J Hematol. 2023;98:1814-1815.
    >> Share


  144. Withdrawal: "Primary prevention of sickle cell disease using preimplantation genetic testing and in vitro fertilization is cost-effective." Christina N. Cordeiro Mitchell, Apoorva Pradhan, Bhuchitra Singh, Rakhi P. Naik, Valerie L. Baker, Sophie M. La
    Am J Hematol. 2023;98:1819.
    >> Share

  145. DI MAURO M, El Hoss S, Nardo-Marino A, Stuart-Smith S, et al
    Males with sickle cell disease have higher risks of cerebrovascular disease, increased inflammation, and a reduced response to hydroxyurea.
    Am J Hematol. 2023;98:E341-E344.
    >> Share

    October 2023
  146. CASIMIR M, Colard M, Dussiot M, Roussel C, et al
    Erythropoietin downregulates red blood cell clearance, increasing transfusion efficacy in severely anemic recipients.
    Am J Hematol. 2023 Oct 4. doi: 10.1002/ajh.27117.
    >> Share

  147. ARCHER NM, Gnangnon B, Mikdar M, Ciuculescu MF, et al
    F-erythrocytes promote Plasmodium falciparum proliferation in sickle cell disease.
    Am J Hematol. 2023;98:1598-1605.
    >> Share

  148. STEINBERG MH, Gladwin MT
    "Severity" in adult sickle cell disease.
    Am J Hematol. 2023;98:1508-1511.
    >> Share

  149. WALSH PS, Brousseau DC, Coleman KD
    Return visits after emergency department treatment for sickle cell pain crises.
    Am J Hematol. 2023;98:E266-E268.
    >> Share

    September 2023
  150. VAN DIJK MJ, van Oirschot BA, Harrison AN, Recktenwald SM, et al
    A novel missense variant in ATP11C is associated with reduced red blood cell phosphatidylserine flippase activity and mild hereditary hemolytic anemia.
    Am J Hematol. 2023 Sep 6. doi: 10.1002/ajh.27088.
    >> Share

  151. PORTER JB, Scrimgeour A, Martinez A, James L, et al
    SLN124, a GalNAc conjugated 19-mer siRNA targeting tmprss6, reduces plasma iron and increases hepcidin levels of healthy volunteers.
    Am J Hematol. 2023;98:1425-1435.
    >> Share

  152. LIU H, Xia L, Weng J, Zhang F, et al
    Efficacy and safety of the C5 inhibitor crovalimab in complement inhibitor-naive patients with PNH (COMMODORE 3): A multicenter, Phase 3, single-arm study.
    Am J Hematol. 2023;98:1407-1414.
    >> Share

  153. ELALFY MS, Hamdy M, Adly A, Ebeid FSE, et al
    Efficacy and safety of early-start deferiprone in infants and young children with transfusion-dependent beta thalassemia: Evidence for iron shuttling to transferrin in a randomized, double-blind, placebo-controlled, clinical trial (START).
    Am J Hematol. 2023;98:1415-1424.
    >> Share

  154. MUSALLAM KM, Lombard L, Kistler KD, Arregui M, et al
    Epidemiology of clinically significant forms of alpha- and beta-thalassemia: A global map of evidence and gaps.
    Am J Hematol. 2023;98:1436-1451.
    >> Share

  155. VON SIEBENTHAL HK, Moretti D, Zimmermann MB, Stoffel NU, et al
    Effect of dietary factors and time of day on iron absorption from oral iron supplements in iron deficient women.
    Am J Hematol. 2023;98:1356-1363.
    >> Share

  156. NYANGASA S, Solomon D, Njiro B, Faisal A, et al
    The rate and pattern of fetal hemoglobin decline adjusted to sickle cell status of newborns in Dar es Salaam, Tanzania: A prospective cohort study.
    Am J Hematol. 2023;98:E241-E243.
    >> Share

  157. PIRAN S, Alhomsi N, Warkentin TE
    Recurrent severe thrombocytopenia in critical illness complicated by hemolysis.
    Am J Hematol. 2023;98:1490-1496.
    >> Share

    August 2023
  158. NAIR M, Choudhury SS, Rani A, Solomi C 5th, et al
    The complex relationship between iron status and anemia in pregnant and postpartum women in India: Analysis of two Indian study cohorts of uncomplicated pregnancies.
    Am J Hematol. 2023 Aug 31. doi: 10.1002/ajh.27059.
    >> Share

  159. AGARWAL S, Stanek JR, Vesely SK, Creary SE, et al
    Pregnancy-related thromboembolism in women with sickle cell disease: An analysis of National Medicaid Data.
    Am J Hematol. 2023 Aug 8. doi: 10.1002/ajh.27045.
    >> Share

  160. PATNAIK MM, Tefferi A
    Luspatercept use for lower risk myelodysplastic syndromes: Active but not enough.
    Am J Hematol. 2023;98:1171-1175.
    >> Share

  161. SACHDEV V, Limerick E, Nguyen ML, Li W, et al
    Cardiac effects 2 years after successful non-myeloablative human leukocyte antigen-matched related donor hematopoietic cell transplants in sickle cell disease.
    Am J Hematol. 2023;98:E219-E221.
    >> Share

  162. ROTH A, Barcellini W, D'Sa S, Miyakawa Y, et al
    Sustained inhibition of complement C1s with sutimlimab over 2 years in patients with cold agglutinin disease.
    Am J Hematol. 2023;98:1246-1253.
    >> Share

  163. LANINO L, Restuccia F, Perego A, Ubezio M, et al
    Real-world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts.
    Am J Hematol. 2023;98:E204-E208.
    >> Share

  164. GROS M, Pondarre C, Arnaud C, Kamdem A, et al
    Lung function after matched-related donor allogeneic hematopoietic stem cell transplantation in children with sickle cell disease.
    Am J Hematol. 2023;98:E212-E215.
    >> Share

  165. LIU A, Kremyanskaya M, Mehrazin R, Si Q, et al
    Erythropoietin-secreting metanephric adenoma presenting as erythrocytosis.
    Am J Hematol. 2023 Aug 1. doi: 10.1002/ajh.27047.
    >> Share

    July 2023
  166. ZHANG L, Zhao J, Li R, Pan H, et al
    Low risk of relapse in aplastic anemia patients after SARS-CoV-2 omicron infection: A prospective NICHE cohort.
    Am J Hematol. 2023 Jul 14. doi: 10.1002/ajh.27028.
    >> Share

  167. MCGLOTHLIN J, Abeykoon J, Al-Hattab E, Ashrani AA, et al
    Bortezomib and daratumumab in refractory autoimmune hemolytic anemia.
    Am J Hematol. 2023 Jul 7. doi: 10.1002/ajh.27025.
    >> Share

  168. POWERS JM, Auerbach M
    When taking iron, a glass of orange juice a day keeps anemia away.
    Am J Hematol. 2023 Jul 4. doi: 10.1002/ajh.27017.
    >> Share

  169. RIBEIL JA, Pollock G, Frangoul H, Steinberg MH, et al
    An integrated therapeutic approach to sickle cell disease management beyond infancy.
    Am J Hematol. 2023;98:1087-1096.
    >> Share

  170. ALLALI S, Elie J, Mayrand L, de Montalembert M, et al
    Sputum IL-6 level as a potential predictor of acute chest syndrome during vaso-occlusive crisis in children with sickle cell disease: Exploratory prospective prognostic accuracy study.
    Am J Hematol. 2023;98:E175-E178.
    >> Share

  171. D'ALESSANDRO A, Nouraie SM, Zhang Y, Cendali F, et al
    In vivo evaluation of the effect of sickle cell hemoglobin S, C and therapeutic transfusion on erythrocyte metabolism and cardiorenal dysfunction.
    Am J Hematol. 2023;98:1017-1028.
    >> Share

    June 2023
  172. URIO F, Nkya S, Mgaya J, Rooks H, et al
    Gender effect on production and enrichment of F cell numbers in sickle cell disease patients in Tanzania.
    Am J Hematol. 2023;98:E139-E141.
    >> Share

  173. PINTO VM, Russo R, Quintino S, Rosato BE, et al
    Coinheritance of PIEZO1 variants and multi-locus red blood cell defects account for the symptomatic phenotype in beta-thalassemia carriers.
    Am J Hematol. 2023;98:E130-E133.
    >> Share

  174. BORDONI V, Casale M, Pinto VM, Carsetti R, et al
    Inflammatory and senescence-associated mediators affect the persistence of humoral response to COVID-19 mRNA vaccination in transfusion-dependent beta-thalassemic patients.
    Am J Hematol. 2023;98:E145-E147.
    >> Share

  175. CHEN PH, Gorshein E, Tormey C, Siddon AJ, et al
    "Double-hit" ineffective erythropoiesis-concurrent beta-thalassemia with alpha-gene triplication and myelodysplastic syndrome with SF3B1 mutation.
    Am J Hematol. 2023;98:984-988.
    >> Share

    May 2023
  176. PEFFAULT DE LATOUR R, Risitano AM
    Complement inhibition in medicine: Hematology and beyond; complement inhibition in hematology: PNH and beyond.
    Am J Hematol. 2023;98 Suppl 4:S3-S4.
    >> Share

  177. KULASEKARARAJ AG, Lazana I
    Paroxysmal nocturnal hemoglobinuria: Where are we going.
    Am J Hematol. 2023;98 Suppl 4:S33-S43.
    >> Share

  178. DUVAL A, Fremeaux-Bacchi V
    Complement biology for hematologists.
    Am J Hematol. 2023;98 Suppl 4:S5-S19.
    >> Share

  179. LEON J, LeStang MB, Sberro-Soussan R, Servais A, et al
    Complement-driven hemolytic uremic syndrome.
    Am J Hematol. 2023;98 Suppl 4:S44-S56.
    >> Share

  180. PANSE J
    Paroxysmal nocturnal hemoglobinuria: Where we stand.
    Am J Hematol. 2023;98 Suppl 4:S20-S32.
    >> Share

  181. DIAMANTOPOULOS PT, Solomou E, Symeonidis A, Pappa V, et al
    The prognostic significance of macrocytosis in patients with myelodysplastic neoplasms.
    Am J Hematol. 2023;98:E119-E122.
    >> Share

  182. POURDIEU C, El Hoss S, Le Roux E, Pages J, et al
    Relevance of Howell-Jolly body counts for measuring spleen function in sickle cell disease.
    Am J Hematol. 2023;98:E110-E112.
    >> Share

  183. GAARTMAN AE, van Tuijn CFJ, Nur E, Vogt L, et al
    The association between renal function decline and disease severity in sickle cell disease.
    Am J Hematol. 2023;98:E95-E97.
    >> Share

    April 2023
  184. TEFFERI A, Vannucchi AM
    JAK2 inhibitor treatment of anemia in myelofibrosis.
    Am J Hematol. 2023 Apr 21. doi: 10.1002/ajh.26934.
    >> Share

  185. AGGARWAL N, Manley AL, Shalhoub R, Durrani J, et al
    Alemtuzumab in relapsed immune severe aplastic anemia: Long-term results of a phase II study.
    Am J Hematol. 2023 Apr 6. doi: 10.1002/ajh.26924.
    >> Share

  186. ONI MO, Archer NM
    Intranasal fentanyl works-Why are we not using it more to treat acute pain in sickle cell disease?
    Am J Hematol. 2023;98:564-565.
    >> Share

  187. REES CA, Brousseau DC, Ahmad FA, Bennett J, et al
    Intranasal fentanyl and discharge from the emergency department among children with sickle cell disease and vaso-occlusive pain: A multicenter pediatric emergency medicine perspective.
    Am J Hematol. 2023;98:620-627.
    >> Share

  188. REDJOUL R, Beckerich F, de Luna G, Leclerc M, et al
    ABO blood barrier to engraftment after allogeneic stem cell transplantation in sickle cell disease: A case-story with two successive HLA-matched sibling donors.
    Am J Hematol. 2023;98:692-696.
    >> Share

    March 2023
  189. RISINGER M, Kim PS, Rodriguez RX, Narvaez Rivas M, et al
    Hemolytic anemia and macrothrombocytopenia: a lipid problem?
    Am J Hematol. 2023 Mar 28. doi: 10.1002/ajh.26916.
    >> Share

  190. RAI P, Okhomina VI, Kang G, Martinez HR, et al
    Longitudinal effect of disease-modifying therapy on left ventricular diastolic function in children with sickle cell anemia.
    Am J Hematol. 2023 Mar 8. doi: 10.1002/ajh.26911.
    >> Share

  191. LANSER L, Plaikner M, Schroll A, Burkert FR, et al
    Tissue iron distribution in patients with anemia of inflammation: results of a pilot study.
    Am J Hematol. 2023 Mar 7. doi: 10.1002/ajh.26909.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016